An international research team led by the University of Bonn has identified and further developed novel antibody fragments against SARS-CoV-2.
- These “nanobodies” are much smaller than classic antibodies— and they, therefore, penetrate the tissue better and can be produced more easily in larger quantities.
- Nanobodies are recombinant, antigen-specific, single-domain, variable fragments of camelid heavy chain-only antibodies.
- Nanobodies are antibody fragments that are so simple that they can be produced by bacteria or yeast, which is less expensive.
- Nanobodies are a novel class of proprietary therapeutic proteins based on single-domain antibody fragments that contain the unique structural and functional properties of naturally-occurring heavy chain only antibodies.
